AbbVie (NYSE:ABBV) Releases Q4 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its fourth quarter 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 3.830-3.870 for the period, compared to the consensus earnings per share estimate of 3.890. The company issued revenue guidance of $18.4 billion, compared to the consensus revenue estimate of $18.3 billion. AbbVie also updated its FY 2026 guidance to 13.950-13.990 EPS.

Analysts Set New Price Targets

Several research analysts have weighed in on ABBV shares. Argus upped their target price on shares of AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Piper Sandler lifted their price objective on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Canaccord Genuity Group raised their target price on shares of AbbVie from $290.00 to $338.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Rothschild & Co Redburn increased their target price on AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $294.67.

AbbVie Trading Up 0.4%

AbbVie stock opened at $290.02 on Tuesday. AbbVie has a 52 week low of $190.75 and a 52 week high of $298.74. The stock has a market cap of $512.41 billion, a P/E ratio of 49.74, a price-to-earnings-growth ratio of 1.31 and a beta of 0.24. The stock has a 50 day moving average of $269.81 and a 200-day moving average of $237.57.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. During the same quarter in the prior year, the firm posted $1.86 earnings per share. AbbVie’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, equities analysts predict that AbbVie will post 13.92 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be issued a $1.82 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. AbbVie’s dividend payout ratio is currently 119.10%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie raised its fiscal 2026 adjusted EPS outlook to $13.95-$13.99, above the prior consensus midpoint, and forecast revenue of $67.8 billion, ahead of the $67.6 billion consensus. Growth from Skyrizi, Rinvoq and neuroscience products is helping offset Humira’s decline. ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
• Positive Sentiment: Multiple analysts raised their price targets following AbbVie’s strong third-quarter results, including RBC to $330, Cantor Fitzgerald to $325, Canaccord Genuity to $338, Leerink Partners to $342 and Morgan Stanley to $346. The firms maintained bullish ratings. Analysts Increase Forecasts on AbbVie
• Positive Sentiment: AbbVie expanded a global license agreement with Brise Pharmaceuticals for next-generation migraine therapies. The deal could be worth up to approximately $757 million and follows positive Phase 3 migraine data published in The Lancet Neurology. AbbVie License Deal With Brise
• Positive Sentiment: AbbVie won a lawsuit challenging certain drug-price-control actions by the U.S. Department of Health and Human Services, potentially reducing regulatory and pricing pressure. AbbVie Wins Drug Price Control Lawsuit
• Neutral Sentiment: Allergan Aesthetics will present nine research abstracts at ASDS 2026, covering aesthetic treatment after medical weight loss, BOTOX Cosmetic and investigational trenibotulinumtoxinE. The event supports AbbVie’s long-term aesthetics pipeline but is unlikely to materially affect near-term earnings. Allergan Aesthetics ASDS 2026 Research
• Negative Sentiment: AbbVie’s fourth-quarter EPS guidance of $3.83-$3.87 is below the $3.89 consensus estimate, despite revenue guidance of $18.4 billion exceeding expectations. The modest earnings shortfall may be the clearest near-term pressure on the shares.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.